Abcuro Inc.’s venture capital investors showed confidence in the ongoing Phase II/III MUSCLE clinical trial of ulviprubart (ABC008) in inclusion body myositis (IBM) by putting their support behind a $
The series C venture capital round that Tessera Therapeutics announced on 19 April – totaling more than $300m, the company said – shows that investors continue to be willing to invest large sums in